Adherence to Oral Hypoglycemic Agents in Hawaii by Lee, Rachel & Taira, Deborah A
VOLUME 2: NO. 2 APRIL 2005
Adherence to Oral Hypoglycemic Agents 
in Hawaii
ORIGINAL RESEARCH
Suggested citation for this article: Lee R, Taira DA.
Adherence to oral hypoglycemic agents in Hawaii. Prev
Chronic Dis [serial online] 2005 Apr [date cited]. Available
from: URL: http://www.cdc.gov/pcd/issues/2005/apr
04_0049.htm.
PEER REVIEWED
Abstract
Introduction
Adherence to oral hypoglycemic agents is essential to
reducing the poor health outcomes of populations at high
risk for developing diabetes and its chronic complications.
The goal of this study was to identify characteristics of
patients in Hawaii least likely to adhere to oral hypo-
glycemic agents.
Methods
This retrospective administrative data analysis includ-
ed prescription refill claims for oral hypoglycemic agents
from January 1, 1999, through June 30, 2003 (n =
20,685). Multivariate logistic regression analysis was
used to examine the relationship between adherence and
patient characteristics.
Results
Adherence was found to be strongly associated 
with age and ethnicity. Relative to the age subset 
55 to 64 years, adherence increased as age increased,
reaching a peak at age 74 (odds ratio [OR] 1.1; 
95% confidence interval [CI], 1.0–1.20). Past the age 
of 85, adherence declined (OR 0.90; 95% CI,
0.82–0.98). Relative to white patients, the odds ratio of
adherence was highest for Japanese patients (OR 1.20;
95% CI, 1.0–1.30) and lowest for Filipino patients (OR
0.78; 95% CI, 0.68–.90). Gender was not associated
with adherence.
Conclusion
Differences in adherence to oral hypoglycemic agents
were found to be related to ethnicity and age. Adherence
was found to be lowest in younger patients and Filipino
patients. This is a significant finding considering that
younger diabetic patients have been shown to have the
poorest glycemic control and worst health outcomes.
Although the literature on adherence to oral hypoglycemic
agents and health outcomes in Filipino patients is limited,
studies support an increased risk for developing diabetes
in this group. This information can be used to target
younger patients and Filipino patients to improve their
adherence to oral hypoglycemic agents.
Introduction
Patient adherence to a prescribed regimen of oral
hypoglycemic agents to prevent diabetes is generally
low and difficult to maintain, even in populations with
adequate access to health care and drug coverage (1,2).
This problem poses serious consequences for Asian-
Pacific Islanders, who have a higher genetic predispo-
sition than whites for developing diabetes and its
chronic complications (3-6). The Asian-Pacific Islander
population in Hawaii is large and heterogeneous, com-
posed of individuals of Japanese, Chinese, Filipino,
Korean, and Hawaiian ancestry. Comparing the 
different ethnic groups in Hawaii that compose the
Asian-Pacific Islander category reveals significant
health disparities among them. Diabetes has been
found to be three to seven times more prevalent in
Hawaiians and three to four times more prevalent in
Filipinos and Japanese than whites (7). In addition,
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Hawaiians have the highest prevalence of diabetes
reported for any Polynesian or part-Polynesian group,
and mixed ancestry has not been shown to diminish
the risk for type 2 diabetes (8,9). Native Hawaiians on
average have less education and lower income and are
more likely to live in rural areas with less access to
medical services than other ethnic groups living in
Hawaii. These aspects of the Native Hawaiian popula-
tion further elevate its risk for developing diabetes
and its chronic complications.
Evidence suggests that dietary and lifestyle changes
place ethnic minorities at higher risk for developing dia-
betes. The Honolulu Heart Program, a study of 8006
Japanese men born from 1900 to 1919, correlated a west-
ernized and sedentary lifestyle with an increased risk for
developing diabetes. These studies found that Japanese
men who retained a Japanese lifestyle and diet were less
likely to develop diabetes than those Japanese men who
followed a westernized lifestyle (10,11).
Different cultural beliefs and dietary practices among
the various ethnic groups in Hawaii affect the outcome of
diabetes and adherence to medications. The literature sug-
gests that traditional cultural beliefs about family and the
social support it provides when family members are ill
play an important role in either encouraging or preventing
individuals from seeking medical care for diabetes (12,13).
Because minority populations and patients facing socioe-
conomic barriers to health care access have been shown to
have the worst adherence to medications and poor
glycemic control (14), determining the association between
ethnicity and adherence to oral hypoglycemic agents
among Japanese, Chinese, Filipino, Hawaiian, and white
patients in Hawaii will help reveal the ethnic disparities
that exist in Hawaii and identify those groups who most
need to be targeted for intervention.
Methods
Study population
The patients in this study were enrollees in a large
health care plan in Hawaii from January 1, 1999, to June
30, 2003, who met their algorithm for diabetes, had drug
coverage, and filled at least one prescription for one of the
following oral hypoglycemic agents: sulfonylurea, met-
formin, thiazolidinedione, and α-glucosidase inhibitors. To
determine if a patient had diabetes, we used a diabetes
algorithm that followed two decision paths. The first path
looked for the presence of a diabetes diagnosis with specif-
ic treatment services; the second identified the presence of
diabetes based on specific drugs and medical supplies, 
provided the member did not have gestational diabetes.
The characteristics that we controlled for were age, gen-
der, ethnicity, island of residence, morbidity level, year of
treatment, and type of coverage (i.e., HMO, PPO, Medicare
cost contract).
Morbidity level was assessed using the Johns Hopkins
University’s Ambulatory Care Groups (ACGs), derived
from the mix of a member’s diagnoses. In the original
study, 51 combinations or ACGs resulted from applying
multivariate techniques to maximize variance explained
in use of services and ambulatory care charges (15). This
method can be applied to large populations with numerous
types of diagnoses to predict ambulatory care use and cost
of care and to determine the burden of morbidity. High
morbidity was defined as a morbidity level of four or five
on a five-point scale.
Sources of data
Patient age, gender, island of residence, morbidity
level, comorbid conditions, and type of coverage were
obtained from administrative data. This data did not
include ethnicity of the patient. Self-reported ethnicity
information was available for a portion of members in
the study population from existing health-plan member
satisfaction surveys. The satisfaction survey was a
mailed questionnaire filled out by members to describe
their experiences with health care services; on that sur-
vey, members were asked to check all that apply among
17 ethnic categories. These categories were chosen to be
consistent with the Hawaii Department of Health’s
Hawaii Health Surveillance Program. In most cases,
members who marked more than one race or ethnicity
were categorized as “mixed.” Any member who marked
Hawaiian, however, was classified as Hawaiian regard-
less of what other categories he or she may have
marked, because so few persons are of Hawaiian-only
ancestry. We examined ethnic differences in oral adher-
ence for the six main ethnic/racial groups in Hawaii:
Japanese, Chinese, whites, Hawaiians, Filipinos, and
Koreans. Members who marked other ethnicities, no
ethnicity, or were mixed but non-Hawaiian were exclud-
ed from the analyses.
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Treatment adherence for this study was calculated
allowing small gaps between prescriptions. The maximum
allowable gaps were based upon possession ratios, calcu-
lated as follows:
Possession ratio = days supplied for first pre-
scription/(fill date of second prescription – fill
date of first prescription)
A claim separated from a previous claim with a posses-
sion ratio of 0.8 or greater was considered adherent.
Days of adherence were calculated from the date of the
first prescription until the end-of-supply of the last claim.
For isolated claims, claims not within a possession ratio of
0.8 of other claims, the days of adherence were taken as
the days of supply on the claim. The days of adherence for
other claims were calculated as follows:
Days of adherence = date of last adherent pre-
scription – date of first prescription + days of
supply on last compliant prescription
The average days of adherence per year were calculated
as the days of adherence divided by the days of enrollment
in a drug plan since the first prescription date. Patients
needed to have some drug enrollment and medical 
enrollment to be in the study. They did not need to be con-
tinuously enrolled for the entire study period. Days of
adherence were looked at and adjusted by days of enroll-
ment on an annual basis. The average number of days of
enrollment per year was 354 days.
Statistical analysis
Multivariate logistic regression analysis was used to
examine the relationship between adherence and patient
characteristics. All analyses were performed using Stata
V7.0 statistical software (StataCorp, College Town, Tex).
Results
Among the 39,536 patients on an oral hypoglycemic
agent, 20,685 unique numbers met the inclusion criteria
for the study (Table 1). The mean age (± SD) of the study
sample was 63.7 years (± 12.01). Of the study sample,
54.4% were male and 45.6% were female. Among the study
sample, 20.7% had high morbidity; 77.3% lived on Oahu,
12.1% on Hawaii, 5.8% on Kauai, 6.3% on Maui, 0.4% on
Lanai, and 0.7% on Molokai. The distributions of oral
hypoglycemic agents were as follows: sulfonylurea 44.0%,
metformin 31.2%, α-glucosidase inhibitors 1.6%, and thia-
zolidinedione 23.2%. During the study period, 19.9% of
patients also used insulin. Of these patients, 16.0% used
sulfonylurea, 19.8% used metformin, 31.0% used α-glu-
cosidase inhibitors, and 33.0% used thiazolidinedione.
Patients on thiazolidinedione and α-glucosidase inhibitors
have a higher percentage of insulin use.
Adherence differed according to drug class, age, ethnic-
ity, and island of residence (Table 2). Overall adherence
to oral hypoglycemic agents was low at 61.4%. Relative to
sulfonylurea, the odds ratio of adherence was highest for
metformin, followed by thiazolidinedione, and lowest for
α-glucosidase inhibitors. Relative to the age subset 55 to
64 years, adherence increased with older patients, reach-
ing a peak at age 74, then decreased for patients aged 85
and older. Age was controlled for because metformin and
thiazolidinedione are less likely to be used among the
elderly due to contraindications and adverse effects.
Japanese patients were the most likely to be adherent,
followed by Chinese, whites (referent group), Hawaiians,
and Filipinos. Relative to Oahu, Lanai had the lowest
odds ratio.
Compared with the fee-for-service members, HMO mem-
bers were less likely to adhere to medication therapy.
Adherence of members with Medicare coverage was simi-
lar to that of members in the fee-for-service plan. Members
with the lowest morbidity level (i.e., fewest comorbid con-
ditions) tended to be the least adherent to medication.
Adherence tended to improve with increased morbidity
but declined for those with the highest morbidity level. Sex
and the year of treatment were not significantly associat-
ed with adherence.
Discussion
Patient adherence to oral hypoglycemic agents is inte-
gral to reducing the health care costs and chronic compli-
cations of diabetes. Identifying which patients are at
greatest risk for nonadherence to oral hypoglycemic agents
is an important first step toward developing interventions
that improve adherence.
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Older patients had better adherence than younger
patients to oral hypoglycemic agents, with adherence
declining after age 85. A possible explanation for the bet-
ter adherence among the older patients is that they are
more knowledgeable and experienced with using the med-
ications. However, with increasing age and burden of dis-
ease, adherence becomes more difficult to maintain over
time. The finding of an association between age and
adherence to oral hypoglycemic agents has helped to iden-
tify younger diabetic patients as a susceptible group
requiring intervention to improve adherence. The diagno-
sis of diabetes made at an earlier age means these indi-
viduals will have an increased duration of exposure to
hyperglycemia and as a consequence increased severity of
microvascular complications (16). In addition, recent
trends show an increased incidence of type 2 diabetes in
younger individuals belonging to minority groups (17).
This is reflected in current screening guidelines that rec-
ommend diabetes testing earlier (before the age of 45) for
anyone belonging to a high-risk group, such as Asian-
Pacific Islanders.
Ethnicity was also found to be a significant factor in
adherence to oral hypoglycemic agents. Japanese patients
had the highest adherence, and Filipino patients had the
lowest adherence. Worrisome about this finding is that
Filipinos in Hawaii have the highest prevalence of dia-
betes among the four largest Asian groups, which include
Chinese, Japanese, Filipino and Korean (18). Among
Filipino males living in Hawaii, diabetes is the third lead-
ing cause of death, and among Filipino females it is the
second leading cause of death (19). More research is need-
ed to understand the risk factors that contribute to
Filipino susceptibility to developing diabetes and the rea-
sons behind the low rates of adherence to oral hypo-
glycemic therapy in this group.
More studies also need to be done on patients living on
the island of Lanai to find out the reasons behind the low
rates of adherence. One possibility to consider is the rural
setting of the island, which poses barriers to health care
access for persons with diabetes.
This study did not examine the effects on adherence of
combination drug therapy either with or without concomi-
tant insulin use. Combination therapy has been shown to
be associated with poorer rates of adherence than
monotherapy (20-21). In clinical practice, sulfonylurea and
metformin are usually prescribed by themselves as a first-
line therapy because these two drugs are the only ones to
demonstrate decreased vascular risk. Furthermore,
although thiazolidinedione and α-glucosidase inhibitors
are indicated for use as monotherapy, they are used more
in combination therapy, thereby contributing to the
decreased rates of adherence in these two medications.
Insulin has been associated with lower adherence rates;
however, it would be premature to make any conclusion at
this point without further data on the use of combination
therapy in this population.
Other limitations to our results are that the database for
ethnicity is not complete, patients may have received free
samples from their physicians, and the use of medical refill
claims is an indirect method of measuring adherence. It is
not known if patients are actually ingesting their medica-
tions; however, filling a prescription is a necessary first
step for doing so. Another limitation was the lack of HbA1c
levels, which would have provided a means for linking
nonadherence with poor health outcomes in the popula-
tion. To be able to link poor health outcomes with nonad-
herence in susceptible groups, such as younger patients
and Filipino patients, would strengthen the conclusion
that these groups are at high risk for the chronic compli-
cations of diabetes and need to be targeted for interven-
tion. In addition, this study did not examine the effects of
combination drug use on adherence.
Despite these limitations, prescription refill claims can
be used as a tool to predict patient characteristics at high-
est risk for low adherence. Previous studies that have
attempted to correlate demographic characteristics such
as race, age, and gender with adherence have had incon-
sistent results (22-24). However, these studies used a
small sample population. This study used a large sample
population, and the trends demonstrated for race and age
were consistent with other studies that used a large sam-
ple population (25-27).
The findings in this study highlight the need to target
younger patients, Filipino patients, and patients living
in rural areas, such as the island of Lanai, for better
glycemic control. Even with adequate access to health
care services and drug coverage, there was low adher-
ence to oral diabetic medications. This is a disturbing
finding considering that the benefit of intensive glycemic
control has been demonstrated by the U.K. Prospective
Diabetes Study (28).
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Tables
Table 1. Characteristics of Patients with Diabetes Taking Oral
Hypoglycemic Agents in Hawaii (n=20,685), January 1, 1999,
to June 30, 2003a
Mean age, years (±SD) 63.7 (± 12.01)
Male 54.4
Female 45.6
High morbidityb 20.7
Island of residence
Oahu 77.3
Hawaii 12.1
Kauai 5.8
Maui 6.3
Lanai 0.4
Molokai 0.7
Oral hypoglycemic agent
Sulfonylurea 44.0
Metformin 31.2
α-glucosidase inhibitors 1.6
Thiazolidinedione 23.2
Insulin use and oral hypoglycemic agent 19.9
Sulfonlyurea 16.0
Metformin 19.8
α-glucosidase inhibitors 31.0
Thiazolidinedione 33.0
aValues are percentages unless otherwise indicated.
bHigh morbidity was defined as a morbidity level of four or five on a 5-point
scale using the Johns Hopkins University’s Ambulatory Care Groups (ACGs).Oral hypoglycemic agent
Sulfonylurea 1.0 (ref)
Metformin 0.76 (0.73-0.78)
α-glucosidase inhibitors 0.42 (0.37-0.46)
Thiazolidinedione 0.48 (0.46-0.49)
Insulin use 0.82 (0.79-0.85)
Sex
Male 1.0 (ref)
Female 0.97 (0.94-1.0)
Age, years
1-18 0.20 (0.02-1.90)
19-24 0.30 (0.13-0.66)
25-34 0.47 (0.39-0.57)
35-44 0.72 (0.67-0.78)
45-54 0.86 (0.83-0.90)
55-64 1.0 (ref)
65-74 1.1 (1.10-1.20)
75-84 1.1 (1.0-1.10)
85+ 0.90 (0.82-0.98)
Race/ethnicity
White 1.0 (ref)
Japanese 1.20 (1.0-1.30)
Chinese 1.0 (0.89-1.20)
Filipino 0.78 (0.68-0.90)
Hawaiian 0.89 (0.77-1.0)
Other 0.87 (0.74-1.0)
Missing data 0.85 (0.76-0.96)
Island of residence
Oahu 1.0 (ref)
Hawaii 1.10 (1.10-1.20)
Kauai 1.10 (1.0-1.20)
Maui 0.98 (0.92-1.0)
Lanai 0.79 (0.62-1.0)
Molokai 0.94 (0.79-1.10)
Morbidityb
Morbidity 1 1.0 (ref)
Morbidity 2 1.30 (1.10-1.50)
Morbidity 3 1.40 (1.20-1.60)
Morbidity 4 1.40 (1.20-1.60)
Morbidity 5 1.30 (1.10-1.60)
Morbidity 6 1.10 (0.95-1.30)
Year
1999 1.0 (ref)
2000 0.97 (0.93-1.0)
2001 1.10 (1.0-1.10)
2002 0.92 (0.87-0.97)
Coverage
Fee-for-service 1.0 (ref)
HMO 0.89 (0.85-0.93)
Medicare 0.98 (0.87-1.10)
aOR = odds ratio; CI = confidence interval. 
bMorbidity level was assessed using the Johns Hopkins University’s
Ambulatory Care Groups.
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Table 2. The Impact of Drug Class and Patient Characteristics on Adherence to Oral Hypoglycemic Agents in Hawaii, January
1, 1999, to June 30, 2003
Adherence
Characteristics OR (95% CI)a
Adherence
Characteristics OR (95% CI)a